# The Institute of Cancer Research

Source: https://onco.cc/institutions/icr-london/  
OnCo record `icr-london` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Discovered more cancer drugs than any other academic institution, including abiraterone and the clinical use of PARP inhibitors.

## Summary

The Institute of Cancer Research in London has discovered more cancer drugs than any other academic institution, including abiraterone through Johann de Bono and the clinical use of PARP inhibitors through Andrew Tutt and Alan Ashworth's synthetic lethality work, and it is the research partner of The Royal Marsden. Its Cancer Therapeutics Unit is also the origin of capivasertib, and its people include Christopher Lord, Kristian Helin, Mel Greaves, Mitch Dowsett and Judith M. Bliss. OnCo links it to olaparib, capivasertib, abiraterone and STAMPEDE, to the DNA replication stress pathway, and to ideas including a non-profit phase 1b combination unit. The valley of death between lab and product is the bottleneck it exists to cross. Its drug discovery, prostate and synthetic lethality programmes are listed below.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: London, GB
- Type: research-institute
- Website: https://www.icr.ac.uk

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Institute_of_Cancer_Research
- Official website: https://www.icr.ac.uk

## Connected records

- institutions: [Breast Cancer Now](https://onco.cc/institutions/breast-cancer-now/), [Cancer Research UK](https://onco.cc/institutions/cruk/), [Cancer Research UK Convergence Science Centre](https://onco.cc/institutions/cruk-convergence-science-centre/), [Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre](https://onco.cc/institutions/guys-st-thomas/), [Imperial College Healthcare NHS Trust / Imperial College London Cancer Research](https://onco.cc/institutions/imperial-cancer-centre/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Capivasertib](https://onco.cc/drugs/capivasertib/), [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Synthetic lethality](https://onco.cc/terms/synthetic-lethality/)
- trials: [CHHiP](https://onco.cc/trials/chhip/), [FAST (5-fraction whole-breast radiotherapy)](https://onco.cc/trials/fast-trial/), [IMPORT LOW](https://onco.cc/trials/import-low/), [InPACT](https://onco.cc/trials/inpact/), [PACE-B](https://onco.cc/trials/pace-b/), [plasmaMATCH](https://onco.cc/trials/plasmamatch/), [STAMPEDE](https://onco.cc/trials/stampede/), [START-A (UK Standardisation of Breast Radiotherapy, trial A)](https://onco.cc/trials/start-a/), [START-B (UK Standardisation of Breast Radiotherapy)](https://onco.cc/trials/start-b/), [TNT (Triple Negative Trial)](https://onco.cc/trials/tnt/)
- people: [Andrew Tutt](https://onco.cc/people/andrew-tutt/), [Axel Behrens](https://onco.cc/people/axel-behrens/), [Christopher Lord](https://onco.cc/people/chris-lord/), [David Dearnaley](https://onco.cc/people/david-dearnaley/), [Dearbhaile Collins](https://onco.cc/people/dearbhaile-collins/), [Ian Chau](https://onco.cc/people/ian-chau/), [James Larkin](https://onco.cc/people/james-larkin/), [Johann de Bono](https://onco.cc/people/johann-de-bono/), [Judith M. Bliss](https://onco.cc/people/judith-bliss/), [Kevin Harrington](https://onco.cc/people/kevin-harrington/), [Kristian Helin](https://onco.cc/people/kristian-helin/), [Mel Greaves](https://onco.cc/people/mel-greaves/), [Mitch Dowsett](https://onco.cc/people/mitch-dowsett/), [Naureen Starling](https://onco.cc/people/naureen-starling/), [Nicholas James](https://onco.cc/people/nicholas-james/), [Nicholas Turner](https://onco.cc/people/nicholas-turner/), [Nicholas van As](https://onco.cc/people/nicholas-van-as/), [Paul Workman](https://onco.cc/people/paul-workman/), [Rosalind Eeles](https://onco.cc/people/ros-eeles/), [Sanjay Popat](https://onco.cc/people/sanjay-popat/), [Stephen Johnston](https://onco.cc/people/stephen-johnston/), [Uwe Oelfke](https://onco.cc/people/uwe-oelfke/)
- key papers: [Assessment of molecular relapse detection in early-stage breast cancer](https://onco.cc/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/), [KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer](https://onco.cc/key-papers/paper-keynote-048-lancet-2019/), [Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer](https://onco.cc/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/), [Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven](https://onco.cc/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/), [Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer](https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/), [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer](https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/)
- bottlenecks: [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- ideas: [A non-profit phase 1b combination unit that any drug owner can use](https://onco.cc/ideas/idea-tr2-combination-utility/), [A precompetitive consortium for the twenty hardest cancer targets](https://onco.cc/ideas/idea-bio1-undruggable-open-consortium/), [An open map of which cancer proteins any drug can stick to](https://onco.cc/ideas/idea-bio1-covalent-ligandability-atlas/), [Attack the backup copy when a tumour has lost the original gene](https://onco.cc/ideas/idea-bio1-paralog-synthetic-lethality/), [Core-funded radiotherapy trials infrastructure with central quality assurance](https://onco.cc/ideas/idea-fund-radiotherapy-trials-infrastructure/), [MRI-first prostate screening with genetic pre-selection](https://onco.cc/ideas/idea-prev-mri-first-prostate-screening-prs/), [Scale up public drug development that takes academic assets to phase 1](https://onco.cc/ideas/idea-fund-national-drug-development-office/), [Use a polygenic risk score to set when screening starts](https://onco.cc/ideas/idea-prev-prs-screening-start-age/)
- pathways: [DNA replication stress](https://onco.cc/pathways/replication-stress/)

---
JSON: https://onco.cc/api/v1/entities/icr-london.json